Literature DB >> 1719089

Location of a new encephalitogenic epitope (residues 43 to 64) in proteolipid protein that induces relapsing experimental autoimmune encephalomyelitis in PL/J and (SJL x PL)F1 mice.

R H Whitham1, R E Jones, G A Hashim, C M Hoy, R Y Wang, A A Vandenbark, H Offner.   

Abstract

Synthetic peptides of proteolipid protein (PLP) were screened for their ability to induce experimental autoimmune encephalomyelitis (EAE) in SJL/J, PL/J, and (SJL x PL)F1 mice, and T cell lines were selected by stimulation of lymph node cells with PLP peptides. PLP 141-151 was found to be less encephalitogenic in SJL/J mice than PLP 139-151, due to deletion of two amino acids from the amino-terminal end. PLP 139-151 immunization induced relapsing EAE in SJL/J and F1 mice but not PL/J mice. In contrast, PLP 43-64 induced relapsing EAE in PL/J and F1 mice but not SJL/J mice. F1 T cell lines specific for either PLP 43-64 or PLP 139-151 adoptively transferred demyelinating EAE to naive F1 recipients. Haplotypes H-2s and H-2u appear to be immunologically co-dominant in F1 mice in the PLP EAE system, which differs from the H-2u dominance in F1 mice in the myelin basic protein EAE system. The identification of a PLP peptide that is encephalitogenic in PL/J mice, in addition to the previous demonstration of PLP peptides that are encephalitogenic for SWR mice (PLP 103-116) and SJL/J mice (PLP 139-151), lends support to a role for PLP as a target Ag in autoimmune demyelinating diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719089

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease.

Authors:  Derrick P McCarthy; Maureen H Richards; Stephen D Miller
Journal:  Methods Mol Biol       Date:  2012

2.  Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor.

Authors:  H Waldner; M J Whitters; R A Sobel; M Collins; V K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 3.  IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis.

Authors:  Bernadette Pöllinger
Journal:  J Mol Med (Berl)       Date:  2012-01-10       Impact factor: 4.599

4.  Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients.

Authors:  Brian Niland; Gabriella Miklossy; Katalin Banki; William E Biddison; Livia Casciola-Rosen; Antony Rosen; Denis Martinvalet; Judy Lieberman; Andras Perl
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

5.  Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis.

Authors:  E Colombo; K Banki; A H Tatum; J Daucher; P Ferrante; R S Murray; P E Phillips; A Perl
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Theiler's virus as a vector for foreign gene delivery.

Authors:  L Zhang; S Sato; J I Kim; R P Roos
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

Authors:  E A Elliott; H I McFarland; S H Nye; R Cofiell; T M Wilson; J A Wilkins; S P Squinto; L A Matis; J P Mueller
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

8.  Experimental autoimmune encephalomyelitis in the mouse.

Authors:  Stephen D Miller; William J Karpus
Journal:  Curr Protoc Immunol       Date:  2007-05

9.  Experimental Autoimmune Encephalomyelitis in Mice.

Authors:  Rachael L Terry; Igal Ifergan; Stephen D Miller
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Minireview: autoimmune responses to myelin proteolipid protein.

Authors:  R A Sobel; J M Greer; V K Kuchroo
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.